Efaproxiral-d6

Efaproxiral-d6 is the deuterium labeled Efaproxiral. Efaproxiral (RSR13) is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy[1][2].

Product Specifications

CAS Number

[1246815-16-6]

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Reactive Oxygen Species (ROS)

Type

Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

O(C(C(O)=O)(C([2H])([2H])[2H])C([2H])([2H])[2H])C1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1

Molecular Formula

C20H17D6NO4

Molecular Weight

347.44

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94 (12) :1777-1784.|[3]Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[ (3,5-disubstituted anilino) carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31 (38) :9141-9.|[4]Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168 (2) :218-25.|[5]Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61 (5) :1503-9.